March 9, 2009 — An updated list of 93 surveillance drug resistance HIV-1 mutations is vital to tracking the AIDS epidemic, according to the results of a study reported in the March issue of PloS ...

Pricing issues have taken precedence as CVS Health’s (NYSE:CVS) pharmacy benefit manager, CVS Caremark, continues to hold off ...

(Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, a spokesperson told Reuters, despite ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, lenacapavir, as a tool in their efforts to fight HIV infections – especially for ...

Gilead stock toppled Thursday after CVS HealthCVS said it won't add the company's new HIV prevention drug, Yeztugo, to its commercial plans for now. The decision is based on clinical, financial and ...

NICE has recommended cabotegravir, the UK’s first long-acting injectable HIV prevention drug, expanding access for people ...